The net clinical benefit (NCB) of anticoagulation use in patients with atrial fibrillation (AF) appears to decrease with advancing age, and this decline can be attributed to competing mortality risk, as shown in a study.
Evolocumab treatment over 2.3 years does not seem to benefit atherosclerotic patients without multiple clinical risk factors or high genetic risk, and these individuals also have a low event rate. However, those with high genetic risk, irrespective of clinical risk, have a high event rate and receive large relative and absolute benefit from this therapy, thus alleviating such risk, according to a study presented at the 2019 Scientific Sessions of the American Heart Association.
High levels of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide can help identify patients at risk of adverse cardiovascular events, according to a study presented at the 2019 Scientific Sessions of the American Heart Association (AHA 2019).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.